toll free: 1800 3070 6727 Email Id: firstname.lastname@example.org
All cancer patients
Ideal for aggressive and advanced cancer patients
Industry leading 592 genes tested
World's most comprehensive NGS test
Tests for Tumor Mutational Load and Microsatellite Instability which is relevant for Immunotherapy response
Sample Requirement: FFPE Block
Illumina Next Generation Sequencing,FISH,CISH,IHC,Pyro-sequencing, Fragment analysis
CAP & CLIA certified laboratory
Reporting time: 2 weeks
Download sample report
BRACA test is a genetic test that detects the presence of a BRCA1 or BRCA2 gene mutation.
BRCA1 and BRCA2 mutations account for about
20 to 25 percent of hereditary breast cancers
About 5 to 10 percent of all breast cancers
15 percent of ovarian cancers overall
A woman’s lifetime risk of developing breast and/or ovarian cancer is greatly increased if
she inherits a harmful mutation in BRCA1 or BRCA2.
Breast cancer: 55% to 65% women who inherit a harmful BRCA1 mutation and around 45% women who inherit a harmful BRCA2 mutation will develop breast
cancer by age 70 years versus a 12% population risk.
Ovarian cancer: 39%women who inherit a harmful BRCA1 mutation and 11% to 17% women who inherit a harmful BRCA2 mutation will develop ovarian cancer by age
70 years versus a 1.3% risk in general population
Cancer patients with BRCA mutations have an up to 64 percent chance of developing a second
breast cancer by age 70.
Breast and ovarian cancers associated with BRCA1 and BRCA2 mutations tend to develop at younger ages than their
A harmful BRCA1 or BRCA2 mutation can be inherited from a person’s mother or father. Each child of a parent who
carries a mutation in one of these genes has a 50 percent chance (or 1 chance in 2) of inheriting the mutation.
BRCA mutations are also linked to Prostate Cancer, Pancreatic Cancer, Acute Myeloid Leukemia, childhood solid
Better understand a patients’ risk for Breast and Ovarian Cancer.
Prescribe more suitable medications at optimal dosages for patients, as needed.
Suggest early lifestyle and diet interventions to help control or prevent Breast and Ovarian Cancer.
65% increase in median overall survival
Multiple technology platform to provide most comprehensive recommendations
31% more accurate in identifying cancer driver mutations
Better treatment recommendation
Complementary consultation with your doctor
Best treatment recommendation
Provides information on pathway analysis
Includes Positive Bioscience expert comments and complementary consulation with your docto
533, Kalbadevi Road,
Mumbai – 400002